|
gptkbp:instanceOf
|
gptkb:drug
cyclin-dependent kinase inhibitor
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EF02
|
|
gptkbp:brand
|
gptkb:Kisqali
|
|
gptkbp:CASNumber
|
1211441-98-3
|
|
gptkbp:chemicalFormula
|
C23H30N8O
|
|
gptkbp:color
|
light yellow
|
|
gptkbp:combines
|
gptkb:fulvestrant
gptkb:letrozole
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
32 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasSMILES
|
CC1=CC(=NC(=N1)N2CCN(CC2)C3=NC4=CC=CC=C4C(=N3)N5CCCCC5)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ribociclib
|
|
gptkbp:indication
|
HER2-negative breast cancer
hormone receptor-positive breast cancer
|
|
gptkbp:KEGGID
|
D10868
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
CDK4/6 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
434.54 g/mol
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:patentExpired
|
2027 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
not recommended in pregnancy
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:proteinBinding
|
70%
|
|
gptkbp:PubChem_CID
|
gptkb:DB11701
gptkb:CHEMBL3545110
44631912
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
alopecia
neutropenia
|
|
gptkbp:storage
|
below 30°C
|
|
gptkbp:UNII
|
P4R3786Q79
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:advanced_hormone_receptor-positive,_HER2-negative_breast_cancer
|
|
gptkbp:bfsLayer
|
6
|